All In Biotech

Drug Trial Radar · NCT04845178

Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache

Last checked: Nov 20, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 797 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

797

Actual

Start

Mar 1, 2021

Primary completion

Jun 19, 2024

Study completion Aug 6, 2024

Sponsor

Lead sponsor
AEON Biopharma, Inc.Industry
Sponsor type
Industry
Collaborators
PPD Development, LP
First posted
Apr 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll 765 patients across approximately 64 sites in the United States, Canada and Australia. Study subjects will be divided evenly across a low dose group, a high dose group and a placebo group. All patients will receive two treatment cycles of ABP-450 or placebo utilizing the Company's novel injection paradigm.

Conditions

  • Migraine

Interventions

  • ABP-450Drug

    ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.

  • PlaceboDrug

    0.9% sodium chloride, sterile, unpreserved, USP/PhEur

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Monthly Migraine DaysTime frame: Baseline to Weeks 21 to 24 Treatment period.
  2. Incidence of Treatment Emergent Adverse EventsTime frame: Baseline to Week 28 - End of Study.

Locations

62 sites in 3 countries. Site status is shown where the registry gives one.

  • MDFirst Research

    Chandler, Arizona

  • Elite Clinical Studies, LLC

    Phoenix, Arizona

  • Arizona Neuroscience Research

    Phoenix, Arizona

  • Clinical Research Consortium Arizona

    Tempe, Arizona

  • Axiom Research LLC

    Colton, California

  • Velocity Research San Diego

    La Mesa, California

  • Collaborative Neuroscience Research

    Long Beach, California

  • Los Angeles Headache Center

    Los Angeles, California

  • Anderson Clinical Research

    Redlands, California

  • Artemis Institute For Clinical Research LLC - San Diego - ClinEdge - PPDS

    San Diego, California

  • Delta Waves LLC - Hunt - PPDS

    Colorado Springs, Colorado

  • Paradigm Clinical Research Centers

    Wheat Ridge, Colorado

  • New England Institute for Neurology and Headache

    Stamford, Connecticut

  • Quality Research of South Florida

    Hialeah, Florida

  • Sandhill Research, LLC

    Lake Mary, Florida

  • Canvas Clinical Research

    Lake Worth, Florida

  • BioMed Research Institute, INC

    Miami, Florida

  • Medical Research Center, LLC

    Miami, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Innovation Medical Research Center

    Palmetto Bay, Florida

  • Clinical Research of Central Florida - ClinEdge - PPDS

    Winter Haven, Florida

  • NeuroTrials Research Inc. - Clinedge - PPDS

    Atlanta, Georgia

  • Drug Studies America, Inc

    Marietta, Georgia

  • Velocity Clinical Research - Boise - ERN - PPDS

    Meridian, Idaho

  • Cedar Crosse Research Center

    Chicago, Illinois

  • Kansas Institute of Research, LLC

    Overland Park, Kansas

  • Crescent City Headache and Neurology Center

    Chalmette, Louisiana

  • Tandem Clinical Research

    Marrero, Louisiana

  • Boston Clinical Trials Inc

    Boston, Massachusetts

  • MedVadis Research

    Waltham, Massachusetts

  • Quest Research Institute - Hunt - PPDS

    Farmington Hills, Michigan

  • Henry Ford Allegiance Neurology

    Jackson, Michigan

  • StudyMetrix Research, LLC

    City of Saint Peters, Missouri

  • Clinvest Research LLC

    Springfield, Missouri

  • Barrett Clinic, P.C. - Clinedge - PPDS

    La Vista, Nebraska

  • Quality Clinical Research

    Omaha, Nebraska

  • Wake Research - CRCN, LLC

    Las Vegas, Nevada

  • Hassman Research Institute - ClinEdge - PPDS

    Berlin, New Jersey

  • Albuquerque Clinical Trials Inc

    Albuquerque, New Mexico

  • Dent Neurologic Institute

    Amherst, New York

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.